2019 SH/EAHP Workshop: Addressing the Challenges of Eosinophilia and Mastocytosis


The WHO classification of neoplasms associated with eosinophilia and mastocytosis has undergone significant revision and update in the past decade. Additionally, the number of ancillary studies available to the pathologist and clinician evaluating a patient with eosinophilia or mastocytosis has expanded dramatically making diagnosis and classification of these processes challenging. The goals of this workshop are to share up-to-date information on the pathologic evaluation and classification of neoplastic and non-neoplastic disorders associated with eosinophilia and mastocytosis. The Workshop will consist of a series of case presentations organized around specific topics as well as keynote lectures on the current challenges and updates in the diagnosis and management of patients with eosinophilia and mastocytosis.


The SH workshop is being held in conjunction with the ASCP annual meeting. This allows you to attend certain ASCP meeting functions in addition to this workshop. Please see schedule and additional registration option details enclosed.


After attending the conference, participants should be able to:

  • Generate a differential diagnosis for peripheral, bone marrow, and lymph node/tissue eosinophilia including both reactive and neoplastic entities. (Knowledge, Competence, Performance, Patient Care)
  • Discuss optimal ancillary testing strategies for the work-up of eosinophilia in the blood and bone marrow. (Knowledge, Competence, Patient Care)
  • Describe the spectrum of features seen in the WHO entities with recurrent genetic abnormalities associated with eosinophilia. (Knowledge, Competence, Performance)
  • Recognize other neoplastic entities, both myeloid and lymphoid, associated with eosinophilia and their diagnostic criteria. (Knowledge, Competence, Patient Care)
  • Utilize the WHO 2017 diagnostic criteria to evaluate and classify cases


This conference is designed for physicians and other health professionals in hematopathology, pathology, molecular diagnostics, cytogenetics, hematology and oncology.



Lectures, Case Studies, Questions and Answers



A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.


The Society for Hematopathology in partnership with the American Society for Clinical Pathology designates this live activity for a maximum of 19.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The American Society for Clinical Pathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.